GLAUKOS Corp
For the period ended May 29, 2025. Filed Apr 15, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 29, 2025 · Filed Apr 15, 2025
GKOS$224.41+2.0%Stored close · as of Nov 6, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the**
**Securities Exchange Act of 1934
Filed by the Registrant☒
Filed by a Party other than the Registrant☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material Under §240.14a-12 |
GLAUKOS CORPORATION
(Name of Registrant as Specified In Its Charter)
Not applicable
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check all boxes that apply): | |
|---|---|
| ☒ | No fee required |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| | | | |
| | |||
|---|---|---|---|
| OUR MISSION | |||
| Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Innovation is at the core of everything we do. Our mantra “We’ll Go First” embodies our commitment and determination to take chances, push the limits of science, and disrupt the legacy treatment paradigms in glaucoma, corneal disorders, and retinal diseases through our pursuit of game-changing technologies. Our strong business foundation and talented teams around the globe give us confidence in our continued ability to execute our long-term strategy and advance our mission for the benefit of patients worldwide. | |||
| 2024 Net Sales | Cash, Equivalents, Restricted Cash and Short-Term Investments(as of 12/31/2024) |
|---|---|
| $383M | $324M |
| NOTICE OF ANNUAL MEETING OF STOCKHOLDERS | ||||||
|---|---|---|---|---|---|---|
| · · · · | ||||||
| · · · | ||||||
| · · · · Our Board of Directors is soliciting your proxy for the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Thursday, May 29, 2025, at 9:00 a.m. Pacific Time, and at any and all postponements or adjournments of the Annual Meeting, for the purposes set forth in the Notice of Annual Meeting of Stockholders accompanying this Proxy Statement. This Proxy Statement and our 2024 Annual Report for the year ended December 31, 2024 (the “2024 Annual Report”) are first being made available to stockholders on or about April 15, 2025. | ||||||
| Thursday, May 29, 20259AM(PT) | | |||||
| | | |||||
| · · Items of business | ||||||
| · · | ||||||
| · · · | ||||||
| · · · · | ||||||
| Admission | | | 1 | Elect the three Class I director nominees named in the accompanying Proxy Statement to serve as directors until the Company’s 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified; | ||
| | | | | |||
| | | | ||||
| Via live audio webcast, please visit:www.virtualshareholdermeeting.com/GKOS2025See “Virtual Annual Meeting—How do I attend the Virtual Annual Meeting?” to learn more about attending the Annual Meeting | | |||||
| | ||||||
| | 2 | Approve, on an advisory basis, the compensation of the Company’s named executive officers; | ||||
| | 3 | Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025; and | ||||
| | 4 | Transact such other business as may properly come before the meeting or any postponements or adjournments thereof. | ||||
| Who may vote | | | | | | |
| | | | | |||
| Stockholders of record at the close of business on April 4, 2025Use the control number on your Notice of Internet Availability of Proxy Materials, or on your proxy card or voting instruction form that accompanied your proxy materials prior to 11:59 p.m., Eastern Time, on May 28, 2025.Instructions on how to vote while participating in the Annual Meeting live via the Internet are posted at www.virtualshareholdermeeting.com/GKOS2025. | | | | |||
| | | | ||||
| | Your vote is important to us.Whether or not you plan to attend the Annual Meeting online, we urge you to submit your proxy or voting instructions now via the Internet, telephone, or mail to instruct how your shares are to be voted at the meeting. See “Questions and Answers About the Proxy Materials and Annual Meeting—How do I vote and what are the voting deadlines?” in the Company’s proxy statement for further instructions. We appreciate your continued support. | |||||
| | | | ||||
| | | BY INTERNETwww.proxyvote.com | | BY TELEPHONE1-800-690-6903 | | BY MAILMail your signed proxy card |
| | | |||||
| | | | ||||
| | | By Order of the Board of Directors,Thomas W. BurnsChairman & Chief Executive Officer Glaukos Corporation One Glaukos Way Aliso Viejo, CA 92656April 15, 2025 | ||||
| | ||||||
| | ||||||
| | ||||||
| | ||||||
| | ||||||
| | | |||||
| | | |||||
| | | |||||
| | | | ||||
Glaukos Corporation | 2025 Proxy Statement | i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.